SNDX · Syndax Pharmaceuticals Inc
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| 2Q26 infusions administered | 5,750 | 2Q26 | — |
| 2Q26 new patients | 300 | 2Q26 | — |
| common shares and prefunded warrants outstanding | 89.4M | As of June 30, 2026 | — |
| Niktimvo net revenue | $60.3M | second quarter of 2026 | — |
|
|
|||
| patients treated commercially since launch | 1,630 | since launch | — |
| Revuforj net revenue | $54.7M | second quarter of 2026 | +91.3% |
|
|
|||
| Syndax collaboration revenue | $18.1M | second quarter of 2026 | +93.4% |
|
|
|||
| Total prescriptions | 1,500 | second quarter of 2026 | — |
| Total prescriptions increase (Revuforj) | 160% | first quarter of 2026 | — |
| Total Revuforj prescriptions | 1,150 | fourth quarter of 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SNDX
this stock
Syndax Pharmaceuticals Inc
|
$1.76B | -6.0% | +627.8% | — | 25.4% |
|
ONC
BeOne Medicines Ltd.
|
$557.05B | +21.5% | +22179.2% | 856.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +19.2% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +7.1% | +20.8% | 20.8 | 3.3% |
|
MRNA
Moderna, Inc.
|
$69.62B | +352.1% | +4.3% | — | 12.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SNDX | +3.5% | -6.9% | -9.0% | +3.7% | -6.0% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +5.5% | -10.2% | -20.2% | +1.6% | -17.8% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.